Please use a PC Browser to access Register-Tadawul
Get It
Unnatural Products, Novartis sign license deal worth up to $1.7 billion for cardiovascular program
Novan, Inc. NOVN |
| 0.00% |
Feb 18 (Reuters) - Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis NOVN.S to develop macrocyclic peptide-based therapies for a cardiovascular program.
